Alzheimer's Imaging Consortium

Presented by the ISTAART Neuroimaging Professional Interest Area
Saturday, July 14, 2012
Vancouver, British Columbia, Canada
8 a.m.- 5 p.m.

Charles DeCarli, Chair, University of California, Davis, United States
Christopher Rowe, Vice Chair, Austin Health, Melbourne, Australia

The Alzheimer's Imaging Consortium (AIC) pre-conference will focus on the clinical application and methodological development of neuroimaging (MRI, PET, SPECT, CT and others) to Alzheimer's disease, other dementias and normal brain aging. The meeting will consist of invited speakers, as well as oral and poster presentations from submitted abstracts. Presentations from young scientists and interactive discussion will be encouraged. The world's leading imaging and non-imaging researchers will discuss topics such as:

• Early and differential diagnosis and the proposal for new criteria.
• Tracking progression and evaluating treatments.
• Asymptomatic stages of Alzheimer's and normal brain aging.
• Cognitive and basic neuroscientific studies: animal imaging, imaging and genetics.
• Multi-modality imaging studies and new imaging methods.
• The latest developments on other dementias such as Lewy body disease and vascular diseases.

This event is organized by the ISTAART Neuroimaging Professional Interest Area.

Target audience

All researchers and clinicians involved in the care of or research on individuals with memory or other cognitive complaints, including but not limited to neurologists, psychiatrists, radiologists, geriatricians and neuropsychologists; as well as researchers, industry and regulatory agencies stakeholders; and others involved in the use of imaging techniques in the study of Alzheimer's disease, related disorders and normal aging.

Learning objectives

At the end of this educational activity, attendees should be able to:

• Identify the importance of structural, functional, and amyloid imaging in the study of Alzheimer's disease.
• Explain how technological developments of imaging methods can be leveraged in the scientific understanding, early detection and tracking of Alzheimer's disease and the evaluation of promising treatments.
• Recognize new developments in multi-modality imaging approaches and challenges involved in using these techniques in the scientific study and clinical evaluation of Alzheimer's disease and related disorders.
• Discuss the application of imaging techniques to the basic sciences (animal studies, genetics, pathology, etc.) for the understanding of brain function in health and disease.

Awards

A limited number of fellowships in the form of complimentary registration are available for young researchers. Awardees will be chosen based on the anonymous reviewers' ratings of their oral or poster abstract and financial need. Additionally, the best oral and poster presentation among this group will be awarded a $500 prize each.

Continuing Medical Education

This activity is jointly sponsored by the Postgraduate Institute for Medicine (PIM) and the Alzheimer's Association.

Scientific sessions are not supported by any commercial entity.

Accreditation statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and the Alzheimer's Association. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of conflicts of interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.